Blocking a Spleen Artery to Treat Stubborn Abdominal Fluid in Cirrhosis
Tests splenic artery embolization for fluid buildup in adults with advanced cirrhosis.
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Boston, United StatesSee the 3 sites
- Trial code
- Registry title
- Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis
- Status
- Not yet recruiting
- People taking part
- 60 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 1 Oct 2030
- Type of study
- Interventional
- Treatments tested
- Proximal Splenic Artery Embolization
- Record updated
- 10 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced cirrhosis whose belly fluid keeps coming back despite water pills and diet, and who need repeated fluid drainage. A TIPS shunt must not be a safe option for them.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Decompensated cirrhosis with portal hypertension of liver-sinusoid origin. Ascites not controlled by the highest tolerated water pills and low-salt diet. Needed large-volume drainage at least 2 times a month on average for at least 3 months in a row. Life expectancy of at least 6 months.
- Earlier treatment
- Must have had maximum tolerated diuretic therapy (spironolactone up to 400 mg/day plus furosemide up to 160 mg/day) and sodium restriction. Must be unable or at high risk to have a TIPS shunt.
Main reasons for not taking part
- Portal hypertension caused by problems before or after the liver sinusoids (for example Budd-Chiari syndrome, schistosomiasis)
- Blood clot in the main portal, splenic or superior mesenteric vein
- Liver transplant listing with MELD-Na of 20 or more, or transplant within 6 months judged highly likely
- Prior splenectomy, prior distal splenic artery embolization, splenic abscess or large splenic infarction
- Active infection, recent bleeding in the digestive tract, pregnancy or breastfeeding
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Age ≥ 18 years at the time of informed consent
- Decompensated cirrhosis confirmed by clinical, laboratory, radiographic, or histologic criteria
- Portal hypertension of sinusoidal origin. Pre-sinusoidal (e.g., idiopathic non-cirrhotic portal hypertension, schistosomiasis) and post-sinusoidal (e.g., Budd-Chiari syndrome, right-heart failure, constrictive pericarditis) etiologies are excluded
- Refractory or recurrent ascites defined as ascites not controlled by maximum tolerated diuretic therapy (spironolactone ≤ 400 mg/day + furosemide ≤ 160 mg/day, or maximum tolerated doses below these limits) and sodium restriction, or diuretic-intractable due to diuretic-induced complications
- Demonstrated large-volume paracentesis (LVP) dependence for ≥ 3 consecutive months prior to screening, with ≥ 2 LVP sessions per month on average during that window, documented in the institutional medical record or in external paracentesis procedure records released to the investigator
- Ineligible or relatively contraindicated for TIPS. Acceptable reasons include but are not limited to: MELD-Na > 18 with additional risk factors, pre-existing or recurrent overt hepatic encephalopathy, advanced age with comorbidity, clinically significant cardiopulmonary disease, or anatomic contraindication
- Life expectancy ≥ 6 months in the judgment of the enrolling investigator
- Able and willing to provide written informed consent and to adhere to the study visit and assessment schedule
- Abdominal cross-sectional imaging (CT or MRI) within 60 days of enrollment confirming patency of the main portal vein and main splenic vein, and absence of findings that would contraindicate PSAE
Who cannot take part
- Active listing for liver transplantation with MELD-Na ≥ 20 at screening, or any listing status in which transplantation within 6 months is judged highly likely by the site transplant team. (Listed participants with MELD-Na < 20 and low anticipated short-term transplant probability may be enrolled with documented site transplant-team concurrence.)
- Pre-existing splenectomy, prior distal splenic artery embolization, or pre-existing splenic abscess, large splenic infarction (≥ 30% of splenic parenchyma), or splenic mass on imaging
- Active or uncontrolled systemic infection, including spontaneous bacterial peritonitis in the prior 14 days, bacteremia in the prior 14 days, or any infection requiring parenteral antibiotics at the time of screening
- Active gastrointestinal bleeding within 14 days, or untreated high-risk esophageal or gastric varices (primary prophylaxis not yet established) - treatable prior to enrollment
- Enrollment in another interventional clinical trial within 30 days or concurrent with this study that could confound endpoints, including TIPS-related trials
- Pre-sinusoidal or post-sinusoidal portal hypertension (e.g., extrahepatic portal vein thrombosis, idiopathic non-cirrhotic portal hypertension, schistosomiasis, Budd-Chiari syndrome, hepatic sinusoidal obstruction syndrome, constrictive pericarditis, right-heart failure)
- Main portal vein thrombosis, splenic vein thrombosis, or superior mesenteric vein thrombosis on screening imaging
- Known severe allergy to iodinated contrast not manageable with standard pre-medication, or contrast contraindication precluding cross-sectional CT imaging
- Hepatocellular carcinoma beyond BCLC Stage A, or any active extrahepatic malignancy with life expectancy < 6 months
- Active substance use disorder other than alcohol or tobacco that, in the investigator's judgment, would preclude protocol adherence. Active alcohol use disorder is not exclusionary but is captured (AUDIT-C) and analyzed as a pre-specified covariate
- Any medical, psychiatric, or social condition that in the investigator's judgment would preclude safe participation or adherence to the protocol
- Severe coagulopathy not correctable to INR ≤ 2.0 and platelets ≥ 30 × 10⁹/L on the day of the procedure
- eGFR < 30 mL/min/1.73 m² not on renal replacement therapy, unless iodinated contrast use can be minimized per site protocol and nephrology concurrence is documented
- Pregnancy or breastfeeding. Participants of childbearing potential must have a negative serum pregnancy test at screening and agree to effective contraception through Month 6
- Age < 18 years
- Unable to provide informed consent and without an appropriate legally authorized representative
Where in United States
- Beth Israel Deaconess Medical CenterBoston, United StatesContact: Vijay Ramalingam, MDNot yet recruiting
- Brigham & Women's HospitalBoston, United StatesContact: Alex Jacobson, MDNot yet recruiting
- Massachusetts General HospitalBoston, United StatesContact: Eric P. Wehrenberg-Klee, MDNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to learn whether a procedure called Proximal Splenic Artery Embolization (PSAE) can lower the need for repeat fluid drainage in adults with cirrhosis and a buildup of fluid in the abdomen (ascites) that is no longer controlled by water pills and diet. Participants in this study have already been told that a standard procedure called Trans jugular Intrahepatic Portosystemic Shunt (TIPS) is not a safe option for them. The main objectives this study aims to answer are:
Read full original descriptionShow less
* Does PSAE lower how often participants need paracentesis, the procedure used to drain fluid from the abdomen? * Does PSAE lower the total amount of fluid drained each month? * Does PSAE change the pressure inside the liver's veins and the blood flow in the liver and spleen? * Does PSAE improve day-to-day symptoms, quality of life, strength, and the ability to do usual activities? * What side effects or complications happen with PSAE in this group of people?
Participants will:
* Undergo one PSAE procedure, during which small coils and/or plugs are placed in the artery that supplies the spleen to slow its blood flow * Have a pressure measurement taken in the liver's veins right before and right after the procedure, with a repeat measurement at 1 month * Attend follow-up visits at 1, 3, and 6 months that include blood tests, ultrasounds, symptoms and quality-of-life questionnaires, and a review of any paracentesis sessions since the last visit * Have a Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) and an ultrasound of the liver and spleen blood vessels at the start of the study and again at 6 months
The group in the trial
- Proximal Splenic Artery EmbolizationTreatment being tested
All enrolled participants undergo a single PSAE procedure. Small embolization coils and/or vascular plugs are placed in the proximal splenic artery to reduce arterial blood flow to the spleen while preserving splenic viability through collateral vessels. HVPG is measured immediately before and after embolization. Oral antibiotic prophylaxis is given for 7 days following the procedure. Participants are followed for 6 months after PSAE, during which paracentesis records, laboratory data, imaging, and patient-reported outcomes are collected.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Prospective, Multi-Center, Single-Arm Clinical Study of Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis
- Plain-language title
- Blocking a Spleen Artery to Treat Stubborn Abdominal Fluid in CirrhosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 10 August 2026